Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 201–300 of 3,636
2024 Clinical practice guidelines for Stable coronary artery disease
Барбараш, О. Л., Karpov, Y. A., Panov, A. V., Akchurin, R. S., Alekyan, B. G., Alekhin, M. N., Aronov, D. M., HARUTYUNYAN, G., Belenkov, Y. N., Boytsov, S. A., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6110 · Cited by 182
The Fauna Of British India, Including Ceylon And Burma. Hymenoptera 2. Ants And Cuckoo-Wasps.
Bingham, C. T. (1903) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.54862 · Cited by 106
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction
Singh, A., Gupta, A., Collins, B., Qamar, A., Monda, K. L., Biery, D. W., López, J. A. G., de Ferranti, S. D., Plutzky, J., Cannon, C. P., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.059 · Cited by 128
Self-citationLeucker, T. M., Blaha, M. J., Jones, S. R., Vavuranakis, M., Williams, M. S., Lai, H. C., Schindler, T. H., Latina, J. M., Schulman, S. P., & Gerstenblith, G. (2020) · Circulation · doi:10.1161/circulationaha.120.046320 · Cited by 111
Acute coronary syndromes: mechanisms, challenges, and new opportunities
Kraler, S. C., Mueller, C. E., Libby, P., & Bhatt, D. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf289 · Cited by 145
Self-citationNonproportional Hazards for Time-to-Event Outcomes in Clinical Trials
Gregson, J., Sharples, L. D., Stone, G. W., Burman, C., Öhrn, F., & Pocock, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1034 · Cited by 104
Wong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 106
ACC/AHA lipid guidelines: Personalized care to prevent cardiovascular disease
Reiter–Brennan, C., Osei, A. D., Uddin, S. M. I., Orimoloye, O. A., Obisesan, O. H., Mirbolouk, M., Blaha, M. J., & Dzaye, O. D. A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.19078 · Cited by 114
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 125
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Harada‐Shiba, M., Curcio, D. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415820 · Cited by 122
Self-citationMarston, N., Gurmu, Y., Melloni, G. E. M., Bonaca, M. P., Gencer, B., Sever, P. S., Pedersen, T. R., KEECH, A. C., Roselli, C., Lubitz, S. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046397 · Cited by 104
Schwartz, G. G., Steg, P. G., Bhatt, D. L., Bittner, V., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Manvelian, G. Z., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.049447 · Cited by 109
Self-citationPCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 119
“However, there is limited evidence for PCSK9 monoclonal antibody in homozygous familial hypercholesterolemia (HoFH), so only evolocumab has been labeled for this indication [33].”
BackgroundThe PCSK9 revolution: Current status, controversies, and future directions
Warden, B. A., Fazio, S., & Shapiro, M. D. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.007 · Cited by 106
Intracranial Atherosclerotic Disease
Yaghi, S. R., Prabhakaran, S., Khatri, P., & Liebeskind, D. S. (2019) · Stroke · doi:10.1161/strokeaha.118.024147 · Cited by 100
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque
Marfella, R., Prattichizzo, F., Sardu, C., Paolisso, P., D’Onofrio, N., Scisciola, L., Grotta, R. L., Frigé, C., Ferraraccio, F., Panarese, I., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.971 · Cited by 108
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
Khan, S. A., Naz, A., Qamar Masood, M., & Shah, R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.018 · Cited by 98
Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
Ugovšek, S., & Šebeštjen, M. (2021) · Biomolecules · doi:10.3390/biom12010026 · Cited by 107
Tremblay, F., Xiong, Q., Shah, S. S., Ko, C., Kelly, K., Morrison, M. S., Giancarlo, C., Ramírez, R. N., Hildebrand, E. M., Voytek, S. B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03508-x · Cited by 125
“These data support the development of a single-dose treatment of hypercholesterolemia with reduction in LDL-C on par or better than approved treatments that require chronic dosing, such PCSK9 monoclonal antibodies 31,32 and small interfering RNA (siRNA) 33 .”
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
Myers, K. D., Farboodi, N., Mwamburi, M., Howard, W. H. R., Staszak, D., Gidding, S. S., Baum, S. J., Wilemon, K. A., & Rader, D. J. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005404 · Cited by 102
A Comprehensive Review of PCSK9 Inhibitors
Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., Gregory, J., & Hashemzadeh, M. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221100107 · Cited by 109
“1%, respectively).(40) Although their safety profiles are comparable, a metaanalysis found evolocumab to be a more potent reducer of LDL-C than alirocumab.”
Background2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 129
Amarenco, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1908837 · Cited by 103
Messas, E., Goudot, G., Halliday, A. W., Sitruk, J., Mirault, T., Khider, L., Saldmann, F., Mazzolai, L., & Aboyans, V. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa162 · Cited by 110
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Cognition After Lowering LDL-Cholesterol With Evolocumab
Gencer, B., Mach, F., Guo, J., Im, K., Ruzza, A., Wang, H., Kurtz, C. E., Pedersen, T. R., KEECH, A. C., Ott, B. R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.039 · Cited by 100
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
Perrot, N., Valerio, V., Moschetta, D., Boekholdt, S. M., Dina, C., Chen, H. Y., Abner, E., Martinsson, A., Manikpurage, H. D., Rigade, S., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.004 · Cited by 91
High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes
Denegri, A., & Boriani, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200717090334 · Cited by 113
Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia
Hu, B., Li, B., Li, K., Liu, Y., Li, C., Zheng, L., Zhang, M., Yang, T., Guo, S., Dong, X., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1418 · Cited by 92
Colchicine’s Role in Cardiovascular Disease Management
Buckley, L. F., & Libby, P. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319851 · Cited by 106
Kim, N. H., Han, K. H., Choi, J., Lee, J., & Kim, S. G. (2019) · BMJ · doi:10.1136/bmj.l5125 · Cited by 91
Zarić, B. L., Radovanović, J., Gluvic, Z. M., Stewart, A. J., Essack, M., Motwalli, O., Gojobori, T., & Isenović, E. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.551758 · Cited by 100
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 116
Ako, J., Hibi, K., Tsujita, K., Hiro, T., Morino, Y., Kozuma, K., Shinke, T., Otake, H., Uno, K., Louie, M. J., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0412 · Cited by 90
Rubino, J., MacDougall, D. E., Sterling, L. R., Hanselman, J. C., & Nicholls, S. J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.023 · Cited by 107
PCSK9 and LRP5 in macrophage lipid internalization and inflammation
Badimón, L., Luquero, A., Crespo, J., Peña, E., & Borrell-Pagés, M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa254 · Cited by 100
Krychtiuk, K. A., Ahrens, I., Drexel, H., Halvorsen, S., Hassager, C., Huber, K., Kurpas, D., Niessner, A., Schiele, F., Semb, A. G., et al. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac123 · Cited by 137
de Isla, L. P., Díaz-Díaz, J. L., Romero-Jiménez, M. J., Muñiz-Grijalvo, O., Mediavilla, J. D., Argüeso, R., Muñoz-Torrero, J. F. S., Rubio, P., Álvarez-Baños, P., Ponte, P. H., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062557 · Cited by 97
Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease
Moriarty, P. M., Gray, J. V., & Gorby, L. K. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.09.010 · Cited by 89
D’Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H. C., Buller, H. R., ten Cate‐Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708035 · Cited by 100
Gencer, B., Mach, F., Murphy, S. A., Ferrari, G. M. D., Huber, K., Lewis, B. S., Ferreira, J., Kurtz, C. E., Wang, H., Honarpour, N., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0882 · Cited by 97
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni-Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 87
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Seidah, N. G., Prat, A., Pirillo, A., Catapano, A. L., & Norata, G. D. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz003 · Cited by 94
Toth, P. P., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-23 · Cited by 117
Sinnaeve, P., Schwartz, G. G., WOJDYLA, D. M., Alings, M., Bhatt, D. L., Bittner, V., Chiang, C., Flores, R. M. C., Díaz, R., Dorobanţu, M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz809 · Cited by 94
Self-citationInflammation and Cardiovascular Disease: The Future
Arnold, N., Lechner, K., Waldeyer, C., Shapiro, M. D., & Köenig, W. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.50 · Cited by 95
Emerging biomarkers for the detection of cardiovascular diseases
Thupakula, S., Nimmala, S. S. R., Ravula, H., Chekuri, S., & Padiya, R. (2022) · The Egyptian Heart Journal · doi:10.1186/s43044-022-00317-2 · Cited by 111
“Biomarkers are a powerful tool for identifying high-risk people, promptly and reliably diagnosing illness conditions, and effectively diagnosing and treating patients [5, 6].”
BackgroundAtherosclerotic plaque stabilization and regression: a review of clinical evidence
Sarraju, A., & Nissen, S. E. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00979-8 · Cited by 119
PCSK9 inhibitors for treating hypercholesterolemia
Pasta, A., Cremonini, A. L., Pisciotta, L., Buscaglia, A., Porto, I., Barra, F., Ferrero, S., Brunelli, C., & Rosa, G. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1702970 · Cited by 94
“FOURIER [27] and ODYSSEY OUTCOMES [28] are two large RCTs designed to evaluate if evolocumab and alirocumab, thanks to the strong influence on LDL-C, can also reduce major cardiovascular AEs and cardiovascular mortality.”
BackgroundMethodInfluentialLacunar stroke: mechanisms and therapeutic implications
Yaghi, S. R., Raz, E., Yang, D., Cutting, S., Grory, B. M., Elkind, M. S. V., & de Havenon, A. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326308 · Cited by 109
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 98
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
Likozar, A. R., Zavrtanik, M., & Šebeštjen, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1775287 · Cited by 102
“The ‘Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk’ (FOURIER) trial [78] included 27,564 patients with stable atherosclerotic disease on high-intensity statin therapies, and investigated the effects of evolocumab and placebo on CV events (mean follow-up, 2.”
BackgroundGibson, C. M., Kastelein, J. J. P., Phillips, A. T., Aylward, P. E., Yee, M. K., Tendera, M., Nicholls, S. J., Pocock, S., Goodman, S. G., Alexander, J. H., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.052 · Cited by 87
Self-citationManagement of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H., & Kasper, P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01028-4 · Cited by 106
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1178-6 · Cited by 127
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 94
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 94
Self-citationWilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.007 · Cited by 97
“HRT with estrogen and progesterone, which lowers Lp(a) concentration, is not recommended in perimenopausal/postmenopausal women to reduce ASCVD risk.(68,118) III (harm) B-R”
BackgroundThe Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
Schuett, K. A., Marx, N., & Lehrke, M. (2023) · Circulation Research · doi:10.1161/circresaha.122.321748 · Cited by 100
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationPaciullo, F., Momi, S., & Gresele, P. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1676863 · Cited by 86
Low-Density Lipoprotein Cholesterol, Cardiovascular Disease Risk, and Mortality in China
Chen, L., Chen, S., Bai, X., Su, M., He, L., Li, G., He, G., Yang, Y., Zhang, X., Cui, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.22558 · Cited by 83
Hoogeveen, R. M., Opstal, T. S. J., Kaiser, Y., Stiekema, L. C. A., Kroon, J., Knol, R. J. J., Bax, W. A., Verberne, H. J., Cornel, J. H., & Stroes, E. S. G. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.06.022 · Cited by 83
Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 72
Self-citationDEEDWANIA, P. C., Murphy, S. A., Scheen, A. J., Badarienė, J., Pineda, A. L., Honarpour, N., KEECH, A. C., Sever, P., Pedersen, T. R., Sabatine, M. S., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.3151 · Cited by 89
Vasyuk, Y. A., Gendlin, G. E., Emelina, E. I., Shupenina, E. Y., Ballyuzek, M. F., Баринова, И. В., Vitsenya, M. V., Davydkin, I. L., Петрович, Д. Д., Duplyakov, D. V., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4703 · Cited by 96
Duell, P. B., Gidding, S. S., Andersen, R. L., Knickelbine, T., Anderson, L., Gianos, E., Shrader, P., Kindt, I., O'Brien, E. C., McCann, D., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.007 · Cited by 89
Self-citationSanz-Cuesta, B. E., & Saver, J. L. (2021) · Stroke · doi:10.1161/strokeaha.121.034576 · Cited by 83
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 98
Hong, C. G., Florida, E. M., Li, H., Parel, P. M., Mehta, N. N., & Sorokin, A. V. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1023651 · Cited by 99
An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
Koren, M. J., Rodriguez, F., East, C., Toth, P. P., Watwe, V., Abbas, C. A., Sarwat, S., Kleeman, K., Kumar, B., Ali, Y., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.382 · Cited by 81
Jukema, R., Ahmed, T. A.-H. N., & Tardif, J. (2019) · BMC Medicine · doi:10.1186/s12916-019-1433-3 · Cited by 87
“For the new lipid-lowering class of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors, the anti-inflammatory effects are less clear [3, 20, 21].”
BackgroundWang, N., Woodward, M., Huffman, M. D., & Rodgers, A. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008552 · Cited by 80
Hernandez‐Boussard, T., Monda, K. L., Crespo, B. C., & Riskin, D. J. (2019) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz119 · Cited by 89
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lópes, R. D., Al‐Khalidi, H. R., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 83
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy
Biccirè, F. G., Häner, J. D., Losdat, S., Ueki, Y., Shibutani, H., Otsuka, T., Kakizaki, R., Hofbauer, T. M., van Geuns, R., Stortecky, S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.019 · Cited by 82
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
Khan, A. W., & Jandeleit-Dahm, K. A. M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01115-w · Cited by 106
“…showed that, in patients with hyper-cholesterolaemia and diabetes, the addition of PCSK9 inhibitors to maximum-tolerated statin therapy significantly lowers plasma LDL cholesterol levels and prevents CVD events without impairing glycaemic control compared with statin therapy alone 138,139,142–145 .”
Application of PCSK9 Inhibitors in Practice
Kaufman, T. M., Warden, B. A., Minnier, J., Miles, J., Duell, P. B., Purnell, J. Q., Wójcik, C., Fazio, S., & Shapiro, M. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.314191 · Cited by 80
Underberg, J., Toth, P. P., & Rodriguez, F. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2117498 · Cited by 78
“use of PCSK9i has resulted in substantial reductions in a composite of CV death and major adverse CV events [22,104,105].”
BackgroundMethodCho, S. M. J., Koyama, S., Honigberg, M. C., Surakka, I. L., Haidermota, S., Ganesh, S., Patel, A. P., Bhattacharya, R., Lee, H., Kim, H. C., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad380 · Cited by 83
Bays, H. E., Kirkpatrick, C. F., Maki, K. C., Toth, P. P., Morgan, R. T., Tondt, J., Christensen, S. M., Dixon, D. L., & Jacobson, T. A. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100108 · Cited by 126
“…analyses from ODYSSEY OUTCOMES (i.e., alir-ocumab) and FOURIER (i.e., evolocumab) supported that regarding patients at high CVD risk, lowering blood LDL-C levels over 50% with proprotein convertase subtilisin kexin-9 inhibitors resulted in about a 15% relative risk reduction of CVD [234,235].”
BackgroundRomeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
“Proprotein convertase subtilisin/kexin type 9 inhibitors include monoclonal antibodies, such as alirocumab or evolocumab, 267,268 and inclisiran, 269 which relies on RNA interference mechanisms to silence hepatic PCSK9 expression.”
Self-citationClinical Interpretation and Management of Genetic Variants
Marian, A. J. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.013 · Cited by 97
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 92
Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis
Zhang, S., Lin, H., Wang, J., Rui, J., Wang, T., Cai, Z., Huang, S.-M., Gao, Y., Ma, T., Fan, R., et al. (2025) · Nature · doi:10.1038/s41586-025-08792-8 · Cited by 104
“Atherosclerosis accounts for more than 60% of cardiovascular fatalities, and the current strategy of controlling LDL-C levels ameliorates only one-third of cardiovascular events 5,6 .”
Tuñón, J., Steg, P. G., Bhatt, D. L., Bittner, V., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Mueller, C. E., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa498 · Cited by 82
Self-citationMacchi, C., Banach, M., Corsini, A., Sirtori, C., Ferri, N., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319831500 · Cited by 75
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.072 · Cited by 75
Clinical Genetic Screening in Adult Patients with Kidney Disease
Cocchi, E., Nestor, J. G., & Gharavi, A. G. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15141219 · Cited by 85
Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction
Schäfer, A., König, T., Bauersachs, J. K., & Akin, M. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101398 · Cited by 80
Mehta, S. R., Paré, G., Lonn, E., Jolly, S. S., Natarajan, M. K., Pinilla‐Echeverri, N., Schwalm, J.-D., Sheth, T., Sibbald, M., Tsang, M., et al. (2022) · EuroIntervention · doi:10.4244/eij-d-22-00735 · Cited by 85
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
Bernardi, S., Marcuzzi, A., Piscianz, E., Tommasini, A., & Fabris, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124058 · Cited by 76
“Two recent trials, the FOURIER and the ODYSSEY OUTCOMES trials, have demonstrated that PCKS9 inhibition significantly reduced the risk of major adverse cardiovascular events in very high risk patients whose LDL remained elevated despite statin therapy at the maximum tolerated dose [75,76].”
ResultEnas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.04.007 · Cited by 79
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Luquero, A., Badimón, L., & Borrell-Pagés, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.639727 · Cited by 80
“The ODYSSEY OUTCOMES study in patients with recent acute coronary syndrome at maximum tolerated dose of statins showed that alirocumab administration was associated with a reduced risk of recurrent ischemic cardiovascular events and also with a reduced mortality (24).”
MethodTriglyceride-rich lipoproteins and cardiovascular diseases
Xu, D., Xie, L., Cheng, C., Xue, F., & Sun, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1409653 · Cited by 73
“However, research indicates a residual risk of 65%-75% of cardiovascular events following statin therapy, and although combining statins with ezetimibe or PCSK9 inhibitors can further reduce the risk by 6% and 15%, respectively, a notable residual burden of vascular disease persists (8 – 10).”
BackgroundInfluential
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

